Immunotherapy

Several immune checkpoint inhibitors are now approved for patients with non–small-cell lung cancer, giving hope to patients living with this disease. Read More ›

After many years in development, the newest type of immunotherapy known as CAR T-cell therapy (or gene therapy) is becoming a mainstream treatment in some types of blood cancer, specifically in leukemia and lymphoma. Read More ›

Immunotherapy brings new hope for patients with Merkel-cell carcinoma, a rare type of skin cancer with few treatment options. Read More ›

New developments in immunotherapy drugs continue to create buzz in the cancer community and beyond. This special issue discusses key developments in immunotherapy, highlighting new advances and providing resources for patients, their family members, and their oncology navigators. Read More ›

Several immune checkpoint inhibitors are now approved for patients with non-small-cell lung cancer, giving hope to patients living with this disease. Read More ›

“CAR T-cell therapy provides an exciting and additional option for patients who have failed more traditional regimens,” says Dr. Gwen Nichols, Chief Medical Officer for Leukemia & Lymphoma Society. Read More ›

The National Comprehensive Cancer Care Network and the American Society of Clinical Oncology recently issued the first set of recommendations for the management of immunotherapy side-effects. Read More ›

Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy. Read More ›

Enter immunotherapy, stage left. This bright star has gained some traction over the past 2 decades, with the promise of more effective and less hazardous ways to combat cancer. Read More ›